“We are delighted to announce that Radiance Biopharma was chosen to present at Biotech Showcase 2025 in San Francisco,” said Robert Brooks, JD, Chief Executive Officer, of Radiance. “We are eager to ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

“Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its ...

III study in treating thyroid eye disease. The privately held company posted top-line efficacy and safety results from a phase IIb/III study of its lead candidate, linsitinib, which hits its primary ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and ...

On the first day of the J.P. Morgan Healthcare Conference, drug executives talked M&A, but also sized up the prospects of ...

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary ...